List of Publicly Traded Nutritional Supplement, Vitamin, and Sports Nutrition Companies

Yes, the U.S. dietary supplement industry continues to grow in 2026. The domestic market is estimated at approximately $69–78 billion in 2025, with projections of 8.5% CAGR through 2033, according to Grand View Research. Key growth drivers include an aging U.S. population prioritizing preventive healthcare, rising interest in personalized nutrition subscriptions, and expanding categories such as nootropics, adaptogens, and companion nutrition products designed for users of GLP-1 weight-loss medications.

GNC Holdings filed for Chapter 11 bankruptcy in June 2020 and was subsequently acquired by a group led by Harbin Pharmaceutical Group, a Chinese firm, taking it private. GNC is no longer publicly traded on U.S. exchanges. Vitamin Shoppe (VSI) was similarly taken private after being acquired by Franchise Group, Inc. in 2019. Both companies are included on this legacy InvestSnips page but are no longer accessible as publicly traded equities on major U.S. exchanges.

MLM-based supplement companies face unique risks compared to traditional retailers or manufacturers. FTC enforcement regarding income disclosure claims and recruiting practices remains an ongoing threat — Herbalife notably settled with the FTC in 2016 for $200 million and agreed to restructure its business model. Beyond regulatory risk, MLM revenue is closely correlated with distributor recruitment cycles, which are difficult to predict and can reverse rapidly during economic downturns or periods of negative media coverage. Thin top-line growth, high distributor churn rates, and geographic concentration in Asia are common structural vulnerabilities for the companies on this list.

Dietary supplements in the U.S. are regulated under the Dietary Supplement Health and Education Act (DSHEA) of 1994, which does not require pre-market FDA approval for supplement products — unlike prescription drugs. Manufacturers are responsible for ensuring the safety and accuracy of their products before bringing them to market. However, the FDA can take action after a product is on the market if it is found to be unsafe or mislabeled. Companies must submit New Dietary Ingredient (NDI) notifications for ingredients not previously marketed before October 1994, and all products must comply with current Good Manufacturing Practice (cGMP) standards.

The rapid adoption of GLP-1 receptor agonist medications (such as Ozempic and Wegovy) for weight loss is both a threat and an opportunity for supplement companies. As a threat, it reduces demand for traditional weight-loss supplement products — a core revenue category for companies like Herbalife and Mannatech. As an opportunity, GLP-1 users experience significant caloric restriction and potential muscle loss, creating demand for high-protein, micronutrient-dense, and muscle-retention supplements. Companies that adapt their product portfolios toward GLP-1 companion nutrition may capture new growth, while those slower to pivot face headwinds in legacy weight-management product lines.

Contract supplement manufacturers, such as Natural Alternatives International (NAII), develop and manufacture custom formulations for third-party brands rather than selling products under their own brand names to consumers. This B2B model gives them insulation from consumer marketing costs and brand volatility, but ties their revenue directly to the contract pipeline and health of their branded-company clients. Branded supplement companies — such as USANA, Nature's Sunshine, or Herbalife — carry their own consumer-facing brands and bear the full burden of marketing, distributor management, and brand reputation, which brings both higher margins and higher risk.

There is no dedicated publicly traded ETF focused exclusively on nutritional supplement and vitamin stocks as of 2026. However, several broader health and wellness ETFs include supplement company exposure as part of their portfolio — such as the Global X Health & Wellness ETF (BFIT) and the iShares U.S. Healthcare ETF (IYH). Investors seeking diversified exposure to the consumer health space without single-stock risk often consider these broader vehicles, though supplement-specific companies typically represent a small portion of any diversified health ETF's holdings.

Key metrics for evaluating nutritional supplement stocks include: active distributor or customer count (especially for MLM-model companies, where distributor trends are the primary leading indicator of revenue direction), revenue per active distributor (a measure of productivity), gross margin trends (which reveal raw material cost pressures), geographic revenue mix (particularly Asia exposure for MLM companies), and cash flow generation relative to reported earnings. Regulatory disclosures in SEC filings — including FTC correspondence and ingredient sourcing risks — are also worth monitoring closely. For comparative metrics including EPS, P/E ratio, and beta across this group, refer to the individual company pages on InvestSnips.